Browsing Tag
dermatology biologics
1 post
Sanofi bets on dosing discipline over rapid onset with amlitelimab’s Phase 3 readout
Sanofi moves amlitelimab toward global filings. Find out what the Phase 3 data mean for investors, competitors, and the dermatology biologics market.